Belantamab Mafodotin

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

What will happen during the trial?

This is a phase I dose escalation and expansion study in RMM and RRMM followed by a single arm phase II expansion in high risk, NDMM. The phase I portion of the protocol will utilize a standard 3+3 dose escalation design to determine the maximum tolerated dose (MTD) and RP2D of the KRd-belantamab mafodotin combination. The phase II portion of the trial is a two-stage design that will assess the efficacy and safety of the combination in newly diagnosed, high-risk MM patients.

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
70 patients (estimated)
Sponsors
Atrium Health's Levine Cancer Institute - Charlotte (Main)
Collaborators
Amgen, GlaxoSmithKline
Tags
Antibody Drug Conjugate (ADC), B-Cell Maturation Antigen (BCMA), High Risk
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1159
NCT Identifier
NCT04822337

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.